Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Union Budget
Budget 2011-2012 Home
Industry Expectations - Budget 2011-2012
Industry Reactions - Budget 2011-2012
Budget 2010-2011
Budget 2010-2011 Home
Industry Expectations - Budget 2010-2011
Industry Reactions - Budget 2010-2011
Contributor's Corner
Bonanza Portfolio
Hemant K Gupta
Krish Bhatt
S A A R T H I
Trinity Investments
Exchange Information
BSE 2009 Holidays
NSE 2009 Holidays
Investor Guide
Depository & Dematerialisation
Grievance Redressal
Investor Guide
SEBI
Trading of Securities
Transfer of Securities
Your Rights
Budget 2009-2010
Budget 2009-2010 Home
Industry Expectations - Budget 2009-2010
Industry Reactions - Budget 2009-2010
Interim Budget 2009-2010 Home
Industry Expectations - Interim Budget 2009
Budget 2008-2009
Railway Budget 2008-2009
Industry Expectations - Budget 2008
Union Budget 2008-2009
Highlights of Budget 2008-2009
Summary of Budget 2008-2009
Industry Reactions - Budget 2008
IPOs
Current IPOs
Past IPOs
IPO Subscription
Mutual Funds
Gold Exchange Traded Fund
MF Unique Holding
Forthcoming Dividends
ELSS Schemes Comparison
Tax Plans
New Fund Offers
Research
Arbitrages
Equity
Market Whispers
Tax Planning
Home
Equity Linked Savings Scheme
Post Office MIS
9% GOI Senior Citizens Savings Scheme
8% Savings (Taxable) Bonds
Kisan Vikas Patra
National Savings Certificate
Public Provident Fund
Research

| More

GlaxoSmithKline Consumer - 3QFY17 Result Update - Weak Demand Accentuated by Demonetization - Reliance Securities

Posted On: 2017-02-16 21:50:44

GlaxoSmithKline Consumer Healthcare (GSK Consumer) has delivered a weak performance in 3QFY17. Its net sales fell by 11.7% to Rs8.2bn, while net profit decreased 8.3% YoY to Rs1.4bn. Marred by demonetization and weak consumer demand environment, its volumes in the core HFD segment fell by 17% in the quarter.

Trimming down our earnings estimate by 7% for FY18E in the wake of poor quarterly performance, we expect GSK Consumer to post modest revenue and earnings CAGR of 2.9% and 6% respectively through FY16-18E. However, considering the Company's market leadership, strong brands and comfortable valuations, we maintain our BUY recommendation on the stock with revised Target Price of Rs5916, which implies an upside of 16% from current levels.

Demonetisation Drags Growth

Overall quarterly volumes declined by 17% YoY, which is attributable to rippling effects of demonetization as the HFD category being discretionary in nature has a higher ticket size compared to conventional FMCG products. Close to half of GSK Consumers' sales come from rural and wholesale channel, which were significant impacted by liquidity crunch post demonetization. The Company supported the trade channels by extending credit and reducing inventory to tide over the crisis situation.

Lower A&P Aid Margins

The Company has largely been able to maintain its overall market shares of ~70%. While Horlicks and its variants have gained market share, Boost has witnessed marginal fall in the same period. Gross margins declined by 110bps YoY to 66.3%, mainly due to higher salience of sachets and commodity inflation. While employee cost remained flat at 13% of sales, A&P spends declined by 220bps YoY to 11.2% of sales. Resultant EBITDA margins rose marginally by 20bps YoY to 15.7%.

Outlook & Valuation

Although, GSK Consumer has had a rough ride in the past two years, we believe that it could recover, going forward on the back of its market leadership, strong brands, increased salience of sachets, improved penetration in North & East and higher pricing power. We expect GSK Consumer to post revenues of Rs39.4bn and Rs43.5bn and net profit of Rs6.9bn and Rs7.6bn in FY17E and FY18E, respectively. Based on expected EPS of Rs180.9, the stock currently trades at 28.2x FY18E earnings. We maintain our BUY recommendation on the stock with revised Target Price of Rs5916, based on 30x Dec-18 EPS.

Shares of GLAXOSMITHKLINE CONSUMER HEALTHCARE LTD. was last trading in BSE at Rs.5118 as compared to the previous close of Rs. 5115.3. The total number of shares traded during the day was 350 in over 128 trades.

The stock hit an intraday high of Rs. 5118.35 and intraday low of 5035. The net turnover during the day was Rs. 1775489.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Reliance Home Finance (RHFL) listed today and it is trading at 4.6x FY2017 book value: Angel Broking
Stocks Picks - TVS Motors, TCS & DCB Bank - Arihant Capital Markets Ltd
Result Update: AksharChem India Ltd - ACCUMULATE - TP Rs.800 - Kotak
Initiating Coverage: VIP Industries Ltd - BUY - TP Rs.325 - Kotak
Company Update: KNR Constructions Ltd - BUY - TP Rs.236 - Kotak
Top Stock Picks by Arihant Capital Market
Chhota (to) MOTA ideas - CALL UPDATE: Venky's India Ltd - BUY - TP Rs.2650 - Kotak
Gabriel India Limited (GABR IN) - Shift in strategy to accelerate the growth - Initiating Coverage - CSEC Research
Banks : Some signs of life; but still weak | Sanctions made in the private corporate sector undertaken by banks/FIs - Kotak
Petroleum minister's clarification on not interfering with auto fuels pricing is a relief
Energy - OMCs (BPCL | HPCL | IOCL): A false but worrying alarm - Kotak
Company Update: Mangalore Refinery and Petrochemicals Ltd (MRPL) - BUY - TP Rs.155 - Kotak
RIL scales uncharted highs - Jio Dhan Dhana Dhan: Angel Broking
Energy-Petroleum consumption: Weakness in industrial fuels; base affects auto fuels - Kotak
Company Update: GE Shipping Company (GESCO) - BUY - TP Rs.530 - Kotak
The Pitch: BSE Ltd - BUY - TP Rs.1170 - Kotak Securities
Cess hike breather for automobile companies, removes hangover on the stocks: Angel Broking
Demerger in CESC Ltd - Kotak PCG Research
Cement:Prices remain soft - Kotak
FIEM Industries Ltd - Result Update - Kotak PCG Research
Ashok Leyland reports fastest growth after Oct-16 - Auto sales numbers analysis: Angel Broking
Bajaj Auto reports recovery in 2W exports - Auto sales numbers analysis: Angel Broking
MSIL August-17 indicates faster recovery from GST blues: Angel Broking
Dr. Reddy's Laboratories, gets a favourable district court verdict for Suboxone: Angel Broking
Company Update: FIEM Industries Ltd - BUY - TP Rs.1254 - Kotak
Sun Pharma: 1QFY2018 Result Update - Angel Broking
Cipla: 1QFY2018 Result Update - Angel Broking
Consumer Products (Cautious): 1QFY18 review - Muted quarter, but better than subdued expectations - Kotak
Result Update: Time Technoplast Ltd - ACCUMULATE - TP Rs.210 - Kotak
Result Update: PNC Infratech Ltd - ACCUMULATE - TP Rs.154 - Kotak
Result Update: Praj Industries Ltd - REDUCE - TP Rs.73 - Kotak
Result Update: Blue Star Ltd - ACCUMULATE - TP Rs.741 - Kotak
Result Update: AIA Engineering Ltd - SELL - TP Rs.1130 - Kotak
Result Update: KNR Constructions Ltd - ACCUMULATE - TP Rs.236 - Kotak
Result Update: Finolex Industries Ltd - BUY - TP Rs.712 - Kotak
HSIL Q1 FY18 Result Update Rating - HOLD - Arihant Capital Markets
CEO & MD of Infosys Resigns: Angel Broking
Indoco Remedies: 1QFY2018 Result Update - Angel Broking
Aurobindo Pharma: 1QFY2018 Result Update - Angel Broking
Insurance: Widening the base - Kotak
Banks : NIM-short term tailwinds and cyclical headwinds : Deciphering the cause of recent compression of NIM - Kotak
Jagran Prakashan Q1 FY18 Result Update Rating - HOLD - Arihant capital Markets
NCLT admits RCOM merger petition with Aircel: Angel Broking
Views on Sun Pharmaceutical Industries Limited 1QFY2018 Results: Angel Broking
Economy: RBI surplus transfer: real danger of fiscal slippage - Kotak
Views on Cadila Healthcare Ltd 1QFY2018 Results: Angel Broking
Views on Cipla Ltd 1QFY2018 Results: Angel Broking
The Pitch Report - Result Update: Balmer Lawrie Company - BUY - TP Rs.289 - Kotak
The Pitch Report - BBTC - BUY - TP Rs1130 - Kotak
Result Update: NMDC - REDUCE - TP Rs.130 - Kotak


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2017